Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)

BACKGROUND: Abiraterone acetate (an androgen biosynthesis inhibitor) plus prednisone is approved for treating patients with metastatic castration-resistant prostate cancer (mCRPC). Study COU-AA-302 evaluated abiraterone acetate plus prednisone versus prednisone alone in mildly symptomatic or asympto...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur Urol
Autors principals: Rathkopf, Dana E., Smith, Matthew R., de Bono, Johann S., Logothetis, Christopher J., Shore, Neal D., de Souza, Paul, Fizazi, Karim, Mulders, Peter F.A., Mainwaring, Paul, Hainsworth, John D., Beer, Tomasz M., North, Scott, Fradet, Yves, Van Poppel, Hendrik, Carles, Joan, Flaig, Thomas W., Efstathiou, Eleni, Yu, Evan Y., Higano, Celestia S., Taplin, Mary-Ellen, Griffin, Thomas W., Todd, Mary, Yu, Margaret, Park, Youn C., Kheoh, Thian, Small, Eric J., Scher, Howard I., Molina, Arturo, Ryan, Charles J., Saad, Fred
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4418928/
https://ncbi.nlm.nih.gov/pubmed/24647231
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2014.02.056
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars